Sangamo Therapeutics (SGMOQ) Other Non-Current Liabilities (2013 - 2025)

Sangamo Therapeutics' Other Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $580000.0 for Q4 2025.

• On a quarterly basis, Other Non-Current Liabilities fell 37.83% year-over-year to $580000.0 in Q4 2025; TTM through Dec 2025 was $580000.0, a 37.83% decrease from a year earlier, with the FY2025 full-year figure at $580000.0, down 37.83% from the prior year.
• Other Non-Current Liabilities retreated to $580000.0 in Q4 2025 per SGMOQ's latest filing, from $977000.0 in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $7.6 million in Q3 2021 and bottomed at $580000.0 in Q4 2025.
• The 5-year median for Other Non-Current Liabilities is $1.2 million (2023), against an average of $2.1 million.
• Across the five-year window, Other Non-Current Liabilities rose 22.93% in 2021 and tumbled 82.9% in 2022, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $1.2 million in 2021, then slipped by 0.82% to $1.2 million in 2022, then slipped by 1.66% to $1.2 million in 2023, then retreated by 21.4% to $933000.0 in 2024, then sank by 37.83% to $580000.0 in 2025.
• Per Business Quant, the three latest SGMOQ Other Non-Current Liabilities figures stand at $580000.0 (Q4 2025), $977000.0 (Q3 2025), and $962000.0 (Q2 2025).